Cambridge Healthtech Institute’s 17th Annual
Antibody-Based Therapies
Compare. Contrast. Combine—The Modality Playbook
May 10-11, 2027
The Antibody-Based Therapies conference brings together the field's leading therapeutic modalities for side-by-side comparison: costimulatory and multispecific T cell engagers, conditional activation and logic-gated platforms, and CAR-T, TCE, and TCR-based approaches—investigating where combination, not competition, is proving to be the winning strategy. For attendees weighing modality choices for their own pipelines, this is where to benchmark what's actually working, and where the field is heading next.
Coverage will include, but is not limited to:
- State-of-the-Industry—Choosing the Best Modality for the Right Patients and Implications for Investors
- Comparative Field Overview from Oncology to Autoimmunity—Antibodies, ADCs, TCEs, Cellular Therapies, mRNA Cancer Vaccines
- Compare & Contrast: Conditionally-Activated, Masking, and Logic-Gated Platforms
- pH-activated vs Protease-activated
- AND vs OR vs NOT-gated strategies
- Costimulatory approaches
- Beyond T cells—NK, Macrophage, Myeloid cell engagers
- Compare & Contrast: CAR-T vs TCEs vs TCR-based Therapies
- Single-Domain Antibodies (VHH/Nanobodies) for Oncology & Beyond
The deadline for priority consideration is October 23, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
- To submit a podium presentation, please click here.
- To become a sponsor, click here.
- To present a poster, click here.
- To sign up to attend, click here.